Treatment of advanced gastric carcinoma with mitomycin and doxorubicin

D. Dalley, C. Erlichman, S. Fine

Research output: Contribution to journalArticlepeer-review

2 Scopus citations


Thirty patients with advanced gastric carcinoma were treated with doxorubicin combined with mitomycin; only four (13%) responded. Myelosuppression was the major toxic effect; there was one toxic death. The overall median survival was 14 weeks (range, 2-42), which is no different from that reported for untreated patients. The combination of doxorubicin and mitomycin alone cannot be recommended for use in patients with advanced gastric carcinoma.

Original languageEnglish (US)
Pages (from-to)897-898
Number of pages2
JournalCancer Treatment Reports
Issue number7
StatePublished - Jan 1 1986

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Treatment of advanced gastric carcinoma with mitomycin and doxorubicin'. Together they form a unique fingerprint.

Cite this